Back to today’s briefing

Story perspectives

FDA's Mifepristone Rule Sparks Controversy Over Mail-Order Abortions

10/16/2025

41 3

Summary

Story summary

The FDA eliminated the in-person dispensing requirement for mifepristone in 2023, triggering controversy.
Critics, including the Alliance Defending Freedom (ADF), say the change facilitates mail-order abortions and undermines state laws.
ADF's lawsuit argues the FDA ignored evidence of higher health risks from mail-order prescriptions.
Testimonies, including Rosalie's, describe personal tragedies and concerns about reproductive coercion.

1 of 1

Story summary

The FDA eliminated the in-person dispensing requirement for mifepristone in 2023, triggering controversy.
Critics, including the Alliance Defending Freedom (ADF), say the change facilitates mail-order abortions and undermines state laws.
ADF's lawsuit argues the FDA ignored evidence of higher health risks from mail-order prescriptions.
Testimonies, including Rosalie's, describe personal tragedies and concerns about reproductive coercion.